BACKGROUND: The known postmenopausal increase in cardiovascular risk may relate in part to changes in fat distribution. Environmental factors which are known to in¯uence cardiovascular disease risk may do so in part by in¯uencing body fat and its distribution. OBJECTIVES: To determine the relationships between tobacco smoking, oestrogen replacement (ERT) and body fat and its distribution in postmenopausal women, independent of genetic factors, physical activity, diet composition and socioeconomic factors. DESIGN: Cross-sectional study in normal post menopausal twins. SUBJECTS: 712 postmenopausal female twins (aged 58.7 AE 0.2 y, body mass index (BMI) 24.4 AE 0.1 kgam 2 ). MEASUREMENTS: Anthropometry; body composition and fat distribution by dual energy x-ray absorptiometry; physical activity, muscle strength, socioeconomic status, dietary composition and dehydroepiandrosterone sulfate (DHEAS). RESULTS: In monozygotic pairs discordant for smoking, intrapair differences in total and central fat were greater than that in concordant pairs, with the lower fat mass in the smoking twin. Overall, smokers had a lower weight, BMI, total and central abdominal fat, despite a higher total and saturated dietary fat intake and similar DHEAS levels. The reduction in central fat was not independent of that in total fat. In monozygotic twins discordant for ERT-use the intrapair differences in total and central body fat were signi®cantly greater than in concordant pairs, with the lower fat measure in the ERT-using twin. Overall, current ERT-users had similar body weight, BMI and total fat compared to non-users but had lower central fat. There were no differences in activity levels, diet or socioeconomic factors between ERT-users and non-users. CONCLUSIONS: Smoking and ERT-use are associated with lower total and central fat in monozygotic postmenopausal twins. In current smokers, the lower central adiposity appears related to its in¯uence on total body fat. In ERT-users, lower central fat may contribute to the reduced cardiovascular risk associated with postmenopausal oestrogen use.
Introduction
Central adiposity is a predictor of cardiovascular and total mortality 1,2 due, at least in part, to its being an integral component of the metabolic syndrome. 3 Whilst premenopausal women are relatively protected from ischaemic heart disease, the postmenopausal years are characterised by an increase in its prevalence (to equal that in men 4 ), paralleled by increases in central fat deposition.
5±8
While factors determining body fat distribution are not completely understood, genetic factors are of primary importance, 9±11 still explaining the majority of the population variance in central adiposity in healthy postmenopausal women. 11 Less is understood about the environmental in¯uences (hormonal, dietary and lifestyle) which could provide means to reduce central adiposity related morbidity. One major risk for cardiovascular disease, cigarette smoking, 12 has been suggested to act partly through an increased waist to hip ratio (WHR) in some, 13 15 but not all 16, 17 studies. Postmenopausal oestrogen replacement therapy (ERT) use is associated with a 50% reduction in cardiovascular risk 18 but improvements in lipids 19±21 and vascular function 22 only partly explain this effect. 20 Studies using dual energy X-ray absorptiometry (DEXA) suggest oestrogen replacement may prevent or reduce central fat deposition in postmenopausal women 23 and this may be an additional mechanism of risk reduction.
Quantifying the in¯uence of such environmental factors on body fat and its distribution is dif®cult, as most previous studies have relied solely on WHR, a measure of central fat limited by its relatively low accuracy as a measure of intraabdominal fat content. 24 26 Importantly, no study has been able to measure the in¯uence of smoking and ERT-use independent of genetic factors.
In this study of a large cohort of healthy Caucasian postmenopausal twins, more direct measures of total and central body fat were used to examine the in¯uence of smoking and oestrogen replacement, independent of physical activity, diet and socioeconomic factors and, most importantly, genetic factors.
Method
Volunteers in a twin study of osteoporosis had their body composition measured at St Thomas' Hospital, London. 27 All were recruited from a national media campaign, gave written informed consent and were unaware of any hypotheses regarding body fat.
Menopausal status (amenorrhoea of more than 12 months) and duration were determined and premenopausal subjects excluded. The mean age ( AE s.d.) at menopause in the cohort was 48.7 AE 4.5 y. An age of 57 (two standard deviations from the mean) was used to de®ne menopausal status in women with hysterectomy prior to the menopause. Data from 712 postmenopausal women are presented.
Twin pairs underwent anthropometry and body composition measurement on the same day. Zygosity was determined by standardised questionnaire and con®rmed with multiplex DNA ®ngerprinting.
Body composition was measured using DEXA (Hologic QDR-2000, Waltham, MA, USA). Individual scans were analysed for central abdominal fat by one investigator (KS) blinded to subject zygosity, described elsewhere. 11 While including some subcutaneous fat, this central fat measure correlates well with that of intraabdominal fat by computed tomography (CT) 28 and with insulin sensitivity by euglycaemic hyperinsulinaemic clamp. 29 In addition, there is recent evidence that subcutaneous abdominal fat itself contributes to part of the metabolic effects of central adiposity 30 and whether the best measure of central fat includes or excludes subcutaneous abdominal fat is not yet resolved. 31 Body composition data were available on 87% of subjects. Both total and central fat can be expressed in kg or percentages; as the results were similar, percentages are usually presented for brevity.
Information regarding both smoking habit (current, past use and duration of use) and ERT-use was available in 96% of subjects. Socioeconomic status was assessed using an UK standardised questionnaire: subjects chose one of nine categories best describing their (and their partners) current occupations.
Dietary composition over the past 12 months was estimated in a random subgroup of subjects (n 252) using a validated food frequency questionnaire (Oxford-type) 32 administered by trained research nurses. Subjects were individually instructed in its use. Questionnaires were analysed using the European Prospective Investigation in Cancer and Nutrition Group (EPIC)-Cambridge nutrient database by the EPIC Group, Institute of Public Health, University of Cambridge.
Activity was assessed in 596 subjects using a standardised questionnaire. 33 The score was derived from home activity (sedentary, sedentary with some exercise, half sedentary-half active or active), weekly sporting activity (nil, 1 h, 2 h medium intensity or 1 h strenuous, 2 h strenuous), weekly physical activity of an intensity producing sweating and whether active 10 y before and at age 30 y (maximum total activity score: 12).
Leg muscle strength was measured using`The Leg Extensor Power Rig' (Medical Physics Department, Queens Medical Centre, Nottingham, UK), which estimates physical function (in Watts) and provides a measure of muscle performance and physical performance not confounded by balance. 34 The best of three efforts was recorded.
Dehydroepiandrosterone sulfate (DHEAS) was measured using a standard radioimmunoassay in a randomly selected subgroup of 326 women (reference range 1.9±9.4 mmolaL).
Monozygotic (MZ) twin pairs provide a powerful tool for determining the in¯uence of environmental factors independent of any genetic effect. Any intrapair differences in body composition in genetically identical individuals must be due to differences in environment. Thus the in¯uences of smoking and ERT individually on body fat may be determined by a comparison of the intrapair differences in MZ twins discordant for the environmental factor to that in concordant pairs, using analysis of variance (ANOVA).
MZ and dizygotic (DZ) twin data were also analysed cross-sectionally. Characteristics in twin pairs are however, generally not independently determined, due to common genetic and environmental in¯uences. If the correlation between twins is not properly accounted for while analysing such data cross-sectionally, parameter estimates though unbiased, will often lead to underestimated standard errors and, consequently, overstated P values. Linear association between variables was determined using generalised estimating equation (GEE) modeling approach. 35 This approach allows for correlation within twin pairs, yields consistent estimates of linear association terms and their corresponding standard errors. Central fat data were adjusted for total fat by the same regression modeling approach and examination of residuals. Comparisons between subgroups were also made using ANOVA.
Results
The characteristics of 712 postmenopausal women (226 MZ pairs, 130 DZ pairs) are shown in Table 1 . The mean age ( AE s.e.m.) was 58.7 AE 0.2 y. One hundred and fourteen subjects were current smokers (16%), 211 (30%) ex-smokers and 387 (54%) lifelong non-smokers. Of the non-smokers, 149 were current ERT-users, 67 were past-users and 358 had never used ERT. Body fat and central adiposity were not related to age (P 0.77 and P 0.06, respectively) or menopause duration (P 0.42 and P 0.12, respectively). Central and total fat were strongly related (r 0.84, P 0.0001). When anthropometric estimates of central fat were compared to the DEXA measure, the WHR was signi®cantly (though weakly) related to central adiposity (r 0.16, P`0.001) but waist circumference and waist-to-height ratio were stronger predictors (r 0.68, P`0.001) (Figure 1 ).
Tobacco consumption
MZ twin analysis. Twenty six MZ pairs discordant for smoking were compared to 134 concordant pairs. For the purpose of assessing the effect of tobacco on fat mass and distribution, pairs discordant for ERTuse were excluded. Discordance for current smoking status was associated with greater intrapair differences in weight (9.4 AE 1.7 kg vs 4.0 AE 0.4, P 0.0001), body mass index (BMI) (3.8 AE 0.7 kgam 2 vs 1.6 AE 0.1, P 0.0001), waist circumference (7.8 AE 1.4 vs 3.9 AE 0.4 cm, P 0.0003), waist-to-height ratio (0.05 AE 0.001 vs 0.03 AE 0.002, P 0.0001), total fat mass (7.8 AE 1.3 kg vs 3.3 AE 0.3 kg), total adiposity (6.3 AE 0.9% vs 2.9 AE 0.3, P 0.0001), central abdominal fat mass (0.69 AE 0.1 kg vs 0.32 AE 0.03) and central adiposity (9.5 AE 1.7% vs 5.2 AE 0.4, P 0.0007) compared to concordant pairs ( Figure 2) . Importantly, within discordant twin pairs, the smoking twin had the lowest total fat and central fat ( Table 2 ). The intrapair differences in WHR were similar in concordant and discordant pairs (data not shown).
Cross-sectional analysis. Overall, current smokers and non-smokers were similar in age and menopause duration (Table 1) . Current cigarette smoking was associated with lower weight, BMI, waist-to-height ratio, total and central fat, without signi®cant differences in WHR (P 0.56) ( Table 1) .
Again excluding ERT-users to eliminate any confounding effect, current smoking was still associated with lower weight (61.2 AE 0.9 vs 63.8 AE 0. The effect of smoking on body fat appeared unrelated to the amount smoked. There was no relationship between pack years and body fat (P 0.96) or central fat (P 0.70). After adjustment for total fat, no additional in¯uence of smoking on central fat was found (P 0.32).
While energy intake did not differ between smokers and non-smokers, dietary protein and fat intake (%) were greater in smokers, the latter due to higher intakes of saturated and monounsaturated fat (Table  3) . Activity levels, muscle strength, energy intake and diet composition were similar in lifelong non-smokers and ex-smokers (data not shown), excepting a slightly higher carbohydrate intake in life-long non-smokers: 49.7 AE 0.4% vs 48.2 AE 0.5, P 0.03.
Past smokers were similar to lifelong non-smokers in body composition, diet and anthropometry (data not shown). Past smokers however, had greater weight (1.8 kg), total body fat mass (2.1 kg), total body adiposity (2.1%), central fat mass (0.17 kg) and central adiposity (3.3%), compared to current smokers (all signi®cant at 95% on F test).
Oestrogen replacement MZ twin analysis. Monozygotic pairs discordant for ERT-use (n 37) were compared to concordant pairs (n 120) (all pairs were concordant for smoking status to eliminate any effect of smoking discordance). Intrapair differences were signi®cantly greater in ERT-discordant pairs in weight (6.1 AE 1.2 kg vs 4.0 AE 0.4, P 0.02), total fat mass (5.4 AE 0.9 kg vs 3.3 AE 0.3, P 0.003), total adiposity (4.3 AE 0.6% vs 3.0 AE 0.3, P 0.02), central abdominal fat mass (0.50 AE 0.06 kg vs 0.32 AE 0.03) compared to concordant pairs (Figure 3) . Importantly, within discordant pairs the ERT-using twin had the lower total and central fat (Table 2 ). Intrapair differences in waist, WHR and waist-to-height ratio did not differ signi®-cantly between ERT concordant and discordant pairs (data not shown).
Cross-sectional analysis. Overall, current users of ERT had a shorter menopause duration than non-users (P 0.03) ( Table 1) . Current smokers were excluded from the analysis to avoid any confounding effect of tobacco consumption. ERT-users and non-users were similar in weight, BMI and total fat, however current ERT use was associated with lower waist circumference, WHR, waist-to-height ratio and central fat by DEXA ( Table 1 ). The shorter duration of menopause in ERT-users did not explain the lower central fat amongst ERT-users (P 0.43).
The lower total and central fat found in non-smoking ERT-users could not be explained by differences in energy intake, dietary composition (Table 3) and activity levels (data not shown), which were similar in ERT-users and non-users. All socioeconomic groups reported similar ever-use of ERT in a subsample of 216 women (data not shown). Muscle strength was signi®cantly greater in ERT-users (87.4 AE 37.2 Watts vs 77.9 AE 31.4, P 0.02) but not when age was included as a covariate. Past ERT-users had greater body weight, BMI, anthropometric measures, total and central abdominal fat than never-users (Table 4) .
Discussion
Central abdominal fat independently predicts total and cardiovascular mortality in women.
1,2 Cardiovascular risk increases postmenopausally 4 as does central fat deposition. 6 While genetic factors still exert a strong it is important to determine the impact of modi®able environmental factors. The relationships between two factors, smoking and ERT-use, and also central adiposity were examined in postmenopausal female twins, independent of genetic in¯uences and other putative environmental effects. The strongest evidence for decreased total and central fat was provided by the discordant MZ twin analyses where current smoking accounted for, on average, 370 g less central fat. Across the cohort as a whole, current smoking was associated with lower weight, BMI, total body fat and central abdominal fat. This study offers the ®rst directly measured evidence that central adiposity, as well as total adiposity, is less in current smokers. The lower central fat was accounted for by the effect of smoking on total body fat.
Previous studies have been contradictory, even suggesting increased central fat, however relying only on anthropometric assessments. It has been suggested smoking contributes to cardiovascular risk and insulin resistance via increased androgen production 36 and increased central adiposity, 13 15 using WHR, a surrogate measure with lesser accuracy in older and obese women. 24±26,37 This study con®rms its inaccuracy and ®nds waist and waist-to-height ratio were better predictors of central fat, as elsewhere. 38 While other androgenic hormones were not measured, DHEAS levels in smokers and non-smokers were similar and behavioural factors (such as activity, muscle strength or energy intake) did not contribute to the observed effect.
Smoking-induced effects on cardiac risk and insulin resistance may be mediated by enhanced lipolysis 39 and lipid effects, 40 consistent with the ®nding that increased insulin resistance and dyslipidaemia are still found in smokers compared to controls matched for BMI and WHR. 17, 41 The seemingly paradoxical association of a diet high in fat (as previously reported 42 ) with lower body fat is consistent with studies showing increased fat oxidation 17 and energy expenditure 38 during smoking and with weight gain following smoking cessation. 13, 43 In this cohort, ex-smokers were 1.8 kg heavier than smokers and had 2.1 kg more body fat.
Strong evidence of the in¯uence of ERT was provided by the MZ twin analysis, where current ERT-use accounted for, on average, 180 g less central fat. Across the cohort ERT-use was associated with lower total body and central abdominal fat. In contrast to the smoking effect, the in¯uence on central fat was independent of that on total fat. Neither differences in diet, activity or socioeconomic factors accounted for Smoking, oestrogen replacement and central adiposity in twins K Samaras et al these differences. Past-ERT-users had greater body mass, total and central fat and it is possible that overweight women avoid or cease ERT for fear of the supposed`side-effect' of weight gain. Oestrogen replacement attenuates the postmenopausal increase in central adiposity. 23 Lesser central adiposity may contribute to the reduction in cardiovascular risk observed in addition to lipid 20, 21 and vascular effects, 22 and helps explain the lower incidence of non insulin dependent diabetes mellitus (NIDDM) amongst ERT-users. 44 In conclusion, this study shows for the ®rst time that current smoking is associated with lower total and central fat, which cannot be attributed to differences in genetic factors, physical activity, diet or muscle strength, using reliable measures. ERT-use is also associated with lower total and central fat, but the central fat effect is independent of that on total fat. Neither genetic factors, diet, activity or social class accounted for this association. Lower central adiposity amongst current-smokers suggests that the increased cardiovascular risk and insulin resistance in smokers does not operate through increased central adiposity. Among ERT-users, lower central fat may contribute to the reduced cardiovascular risk observed with postmenopausal oestrogen replacement therapy. Randomised prospective studies may clarify these effects further, but while possible with oestrogen replacement, are unlikely with smoking.
